11 results on '"Bogani, Giorgio"'
Search Results
2. Laser Therapy in Heavily Treated Oncological Patients Improves Vaginal Health Parameters.
- Author
-
Di Stanislao, Marco, Coada, Camelia Alexandra, De Terlizzi, Francesca, Di Costanzo, Stella, Fiuzzi, Enrico, Mezzapesa, Francesco, Dondi, Giulia, Paoli, Damiano, Damiani, Gianluca Raffaello, Raspagliesi, Francesco, Bogani, Giorgio, Ditto, Antonino, Morganti, Alessio Giuseppe, De Iaco, Pierandrea, and Perrone, Anna Myriam
- Subjects
BREAST tumor treatment ,VAGINAL disease treatment ,PELVIC tumors ,RADIOTHERAPY ,VAGINA ,T-test (Statistics) ,STATISTICAL significance ,RESEARCH funding ,VISUAL analog scale ,HUMAN sexuality ,QUESTIONNAIRES ,CANCER patients ,TREATMENT duration ,TREATMENT effectiveness ,CHI-squared test ,DESCRIPTIVE statistics ,FEMALE reproductive organ tumors ,VAGINAL diseases ,LASER therapy ,LONGITUDINAL method ,SEX customs ,ONCOLOGY nursing ,QUALITY of life ,ANALYSIS of variance ,WOMEN'S health ,DATA analysis software - Abstract
Simple Summary: Patients diagnosed with gynecological and breast cancer undergo multimodal treatments leading to estrogen deprivation and vaginal damage in case of radiotherapy, resulting in significant impairments of vulvo-vaginal function. Non-ablative intravaginal CO2 laser is a promising technique for VVA (vulvo-vaginal atrophy) in breast cancer, gynecological and other pelvic cancer survivors. In this study we explored the effectiveness and the long-term effects of repeated cycles of laser therapy. This therapeutic regimen could represent an effective treatment option for patients with limited therapeutic alternatives due to the hormone-sensitivity frequently showed by these cancers. This study aimed to investigate the efficacy and duration of multiple non-ablative intravaginal CO2 laser (V-lase
® ) cycles in breast cancer patients, gynecological and other pelvic cancers previously subjected to multiple oncological treatments. This prospective study enrolled women under the age of 65 years who reported vaginal symptoms. Data on the Vaginal Health Index (VHI), vaginal length (VL), vaginal pain measured using a Visual Analog Scale (VAS), and the Female Sexual Function Index (FSFI) were collected at baseline and before each laser application, and at subsequent follow-up visits. A total of 170 laser applications were performed on 113 women with various types of cancer. Most patients (57.5%) had received radiotherapy-based treatments before receiving laser treatment. Vaginal health parameters and sexual function improved significantly with each laser application. However, a temporary decline in these improvements occurred during the intervals between cycles. Such worsening was reversed with the subsequent cycle in all groups of patients, irrespective of the type of oncological treatments they had undergone. Multiple course vaginal laser therapy showed promising results as a potential treatment for vaginal atrophy in heavily treated gynecological and breast cancer patients, necessitating further research to determine the optimal time interval between cycles to ensure sustained positive effects. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
3. Management for Cervical Cancer Patients: A Comparison of the Guidelines from the International Scientific Societies (ESGO-NCCN-ASCO-AIOM-FIGO-BGCS-SEOM-ESMO-JSGO).
- Author
-
Restaino, Stefano, Pellecchia, Giulia, Arcieri, Martina, Bogani, Giorgio, Taliento, Cristina, Greco, Pantaleo, Driul, Lorenza, Chiantera, Vito, Ercoli, Alfredo, Fanfani, Francesco, Fagotti, Anna, Ciavattini, Andrea, Scambia, Giovanni, and Vizzielli, Giuseppe
- Subjects
MEDICAL protocols ,HYSTERECTOMY ,CERVIX uteri tumors ,INTERPROFESSIONAL relations ,DISEASE management ,GYNECOLOGIC care ,CANCER patient medical care ,SENTINEL lymph nodes ,ABDOMINAL surgery ,IMMUNOTHERAPY ,INTERNATIONAL agencies ,MEDICAL societies ,MINIMALLY invasive procedures ,HEALTH care teams ,PATIENT aftercare - Abstract
Simple Summary: Cervical cancer, a very aggressive gynecological malignancy that also affects young women, remains significantly prevalent despite worldwide efforts in HPV vaccination campaigns. Cervical cancer research is experiencing a period of significant change, with intense ongoing debates on issues that could potentially transform current guidelines. Therefore, in light of these changes, guidelines and protocols will soon need significant updates. Hence, this paper aims to summarize and compare the most recent recommendations published by international gynecological oncology societies for patients with cervical cancer. A comparative analysis of American, Asian, and European guidelines was conducted to evaluate the different recommendations for diagnostic, surgical, medical, and follow-up management. Cervical cancer continues to have a significant incidence, despite global efforts in HPV vaccination campaigns. Managing this condition involves a diverse team of healthcare professionals. Research in this field is undergoing a period of great revolution in multiple areas, and international guidelines will soon have to adapt to new scientific evidence. This could be true mainly in locally advanced stages, and it could also be true for minimal invasive surgery. This paper aims to summarize and compare the most recent recommendations published by international gynecological oncological societies for patients with cervical cancer. From their comparison, common aspects and disagreements emerged, especially in the diagnostic pathway and follow-up strategies. Several issues that remain to be debated in the literature were addressed and compared, highlighting similarities and differences, from the role of the sentinel lymph node in early stages to that of the adjuvant hysterectomy in locally advanced tumors. On the surgical side, for this last subset of patients, currently, a laparotomic approach is recommended. At the same time, the advent of immunotherapy has just opened up new and promising scenarios in systemic treatment for locally advanced cervical cancer, and international guidelines will soon introduce it into their algorithms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Concurrent Endometrial Cancer in Women with Atypical Endometrial Hyperplasia: What Is the Predictive Value of Patient Characteristics?
- Author
-
Giannella, Luca, primary, Piva, Francesco, additional, Delli Carpini, Giovanni, additional, Di Giuseppe, Jacopo, additional, Grelloni, Camilla, additional, Giulietti, Matteo, additional, Sopracordevole, Francesco, additional, Giorda, Giorgio, additional, Del Fabro, Anna, additional, Clemente, Nicolò, additional, Gardella, Barbara, additional, Bogani, Giorgio, additional, Brasile, Orsola, additional, Martinello, Ruby, additional, Caretto, Marta, additional, Ghelardi, Alessandro, additional, Albanesi, Gianluca, additional, Stevenazzi, Guido, additional, Venturini, Paolo, additional, Papiccio, Maria, additional, Cannì, Marco, additional, Barbero, Maggiorino, additional, Fambrini, Massimiliano, additional, Maggi, Veronica, additional, Uccella, Stefano, additional, Spinillo, Arsenio, additional, Raspagliesi, Francesco, additional, Greco, Pantaleo, additional, Simoncini, Tommaso, additional, Petraglia, Felice, additional, and Ciavattini, Andrea, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Long-Term Follow-Up Outcomes in Women with In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix Undergoing Conservative Treatment—Cervical Adenocarcinoma Study Group Italian Society of Colposcopy and Cervico-Vaginal Pathology.
- Author
-
Giannella, Luca, Delli Carpini, Giovanni, Di Giuseppe, Jacopo, Grelloni, Camilla, Bogani, Giorgio, Dri, Marco, Sopracordevole, Francesco, Clemente, Nicolò, Giorda, Giorgio, De Vincenzo, Rosa, Evangelista, Maria Teresa, Gardella, Barbara, Dominoni, Mattia, Monti, Ermelinda, Alessi, Chiara, Alessandrini, Lara, Guerriero, Angela, Pagan, Alessio, Caretto, Marta, and Ghelardi, Alessandro
- Subjects
ADENOCARCINOMA ,CONSERVATIVE treatment ,UTERINE tumors ,CERVIX uteri tumors ,CANCER invasiveness ,VAGINA ,LOGISTIC regression analysis ,EVALUATION of medical care ,TREATMENT effectiveness ,RETROSPECTIVE studies ,KAPLAN-Meier estimator ,LOG-rank test ,ODDS ratio ,LONGITUDINAL method ,COLPOSCOPY ,RESEARCH methodology ,WOMEN'S health ,CONFIDENCE intervals ,DATA analysis software ,SURVIVAL analysis (Biometry) ,CARCINOMA in situ ,PATIENT aftercare ,CERVIX uteri - Abstract
Simple Summary: In situ/microinvasive adenocarcinoma of the uterine cervix represents the majority of cervical glandular lesions and can be treated conservatively. In contrast to squamous lesions, approximately 15–20% of glandular disease may be HPV-negative and therefore associated with a worse prognosis. Furthermore, up to 4% of cases may show recurrence after three years of follow-up. Given the abovementioned risk, knowing the predictive factors of disease recurrence becomes crucial for post-treatment management. In the present study, HPV testing in follow-up was the best predictor for recurrences in women with in situ/microinvasive AC undergoing conservative treatment. So, its use in clinical practice is of pivotal importance. However, attention should be paid to non-high-risk HPV women in follow-up with non-usual-type histopathology, given that it seems to represent a sub-population at increased risk of recurrences. Objective: The present study aimed to assess long-term follow-up outcomes in women with in situ/microinvasive adenocarcinoma (AC) of the uterine cervix treated conservatively. Methods: Retrospective multi-institutional study including women with early glandular lesions and 5-year follow-up undergoing fertility-sparing treatment. Independent variables associated with recurrence were evaluated. Logistic regression analysis and Kaplan–Meier survival analysis with Logrank test were performed. Results: Of 269 women diagnosed with in situ/microinvasive AC, 127 participants underwent conservative treatment. During follow-up, recurrences were found in nine women (7.1%). The only factor associated with recurrence during follow-up was positive high-risk Human Papillomavirus (hr-HPV) testing (odds ratio 6.21, confidence interval 1.47–26.08, p = 0.012). HPV positivity in follow-up showed a recurrence rate of 21.7% against 3.8% in patients who were HPV-negative (p = 0.002, Logrank test). Among women with negative high-risk HPV tests in follow-up, recurrences occurred in 20.0% of non-usual-type histology vs. 2.1% of usual-type cases (p = 0.005). Conclusion: HPV testing in follow-up is of pivotal importance in women with early glandular lesions undergoing conservative treatment, given its recurrence predictive value. However, women who are high-risk HPV-negative in follow-up with non-usual-type histopathology may represent a sub-population at increased risk of recurrences. Further studies should confirm these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix and HPV-Type Impact: Pathologic Features, Treatment Options, and Follow-Up Outcomes—Cervical Adenocarcinoma Study Group (CAS-Group)
- Author
-
Giannella, Luca, primary, Delli Carpini, Giovanni, additional, Di Giuseppe, Jacopo, additional, Bogani, Giorgio, additional, Sopracordevole, Francesco, additional, Clemente, Nicolò, additional, Giorda, Giorgio, additional, De Vincenzo, Rosa Pasqualina, additional, Evangelista, Maria Teresa, additional, Gardella, Barbara, additional, Dominoni, Mattia, additional, Monti, Ermelinda, additional, Alessi, Chiara, additional, Alessandrini, Lara, additional, Pagan, Alessio, additional, Caretto, Marta, additional, Ghelardi, Alessandro, additional, Amadori, Andrea, additional, Origoni, Massimo, additional, Barbero, Maggiorino, additional, Raspagliesi, Francesco, additional, Simoncini, Tommaso, additional, Vercellini, Paolo, additional, Scambia, Giovanni, additional, and Ciavattini, Andrea, additional
- Published
- 2023
- Full Text
- View/download PDF
7. Concurrent Endometrial Cancer in Women with Atypical Endometrial Hyperplasia: What Is the Predictive Value of Patient Characteristics? †.
- Author
-
Giannella, Luca, Piva, Francesco, Delli Carpini, Giovanni, Di Giuseppe, Jacopo, Grelloni, Camilla, Giulietti, Matteo, Sopracordevole, Francesco, Giorda, Giorgio, Del Fabro, Anna, Clemente, Nicolò, Gardella, Barbara, Bogani, Giorgio, Brasile, Orsola, Martinello, Ruby, Caretto, Marta, Ghelardi, Alessandro, Albanesi, Gianluca, Stevenazzi, Guido, Venturini, Paolo, and Papiccio, Maria
- Subjects
RESEARCH ,HYSTERECTOMY ,AGE distribution ,UTERINE diseases ,RETROSPECTIVE studies ,REGRESSION analysis ,DIABETES ,ENDOMETRIAL tumors ,SYMPTOMS ,PREDICTION models ,HISTOLOGY ,ARTIFICIAL neural networks ,RECEIVER operating characteristic curves ,BODY mass index ,COMORBIDITY ,WOMEN'S health ,DISEASE risk factors ,EVALUATION - Abstract
Simple Summary: The rate of concurrent endometrial cancer (EC) in women with atypical endometrial hyperplasia (AEH) is not negligible. Furthermore, among women with EC, about 12% may have a high-risk disease requiring lymph node status assessment. Given that endometrial sampling cannot exclude EC in women with AEH, knowing variables that increase the risk of malignancy can be helpful in clinical practice. Some patient characteristics were associated with this occurrence, representing possible risk factors on which to adjust treatment planning. No prediction models with internal validation showed the impact of patient characteristics in predicting EC after a preoperative diagnosis of AEH. The present study, using regressions and artificial neural networks, found recurrent patient characteristics in women with EC. However, they likely do not contain good/optimal discriminating information. Future predictive models should include other individual factors (e.g., genotypic variables) to move toward more personalized medicine. Background: The rate of concurrent endometrial cancer (EC) in atypical endometrial hyperplasia (AEH) can be as high as 40%. Some patient characteristics showed associations with this occurrence. However, their real predictive power with related validation has yet to be discovered. The present study aimed to assess the performance of various models based on patient characteristics in predicting EC in women with AEH. Methods: This is a retrospective multi-institutional study including women with AEH undergoing definitive surgery. The women were divided according to the final histology (EC vs. no-EC). The available cases were divided into a training and validation set. Using k-fold cross-validation, we built many predictive models, including regressions and artificial neural networks (ANN). Results: A total of 193/629 women (30.7%) showed EC at hysterectomy. A total of 26/193 (13.4%) women showed high-risk EC. Regression and ANN models showed a prediction performance with a mean area under the curve of 0.65 and 0.75 on the validation set, respectively. Among the best prediction models, the most recurrent patient characteristics were age, body mass index, Lynch syndrome, diabetes, and previous breast cancer. None of these independent variables showed associations with high-risk diseases in women with EC. Conclusions: Patient characteristics did not show satisfactory performance in predicting EC in AEH. Risk stratification in AEH based mainly on patient characteristics may be clinically unsuitable. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Diagnostic Accuracy of Magnetic Resonance Imaging in the Pre-Operative Staging of Cervical Cancer Patients Who Underwent Neoadjuvant Treatment: A Clinical–Surgical–Pathologic Comparison
- Author
-
Ditto, Antonino, primary, Leone Roberti Maggiore, Umberto, additional, Evangelisti, Giulio, additional, Bogani, Giorgio, additional, Chiappa, Valentina, additional, Martinelli, Fabio, additional, and Raspagliesi, Francesco, additional
- Published
- 2023
- Full Text
- View/download PDF
9. Management of Patients Diagnosed with Endometrial Cancer: Comparison of Guidelines.
- Author
-
Restaino, Stefano, Paglietti, Chiara, Arcieri, Martina, Biasioli, Anna, Della Martina, Monica, Mariuzzi, Laura, Andreetta, Claudia, Titone, Francesca, Bogani, Giorgio, Raimondo, Diego, Perelli, Federica, Buda, Alessandro, Petrillo, Marco, Greco, Pantaleo, Ercoli, Alfredo, Fanfani, Francesco, Scambia, Giovanni, Driul, Lorenza, and Vizzielli, Giuseppe
- Subjects
MEDICAL protocols ,MOLECULAR biology ,TUMOR classification ,ENDOMETRIAL tumors ,HEALTH equity ,TUMORS - Abstract
Simple Summary: Endometrial cancer has a high epidemiological impact, and its management is part of everyday clinical practice. International guidelines have been arranged over the years according to major recent discoveries. The application of the guidelines released by different international gynecological societies is still matter of debate as they diverge in many issues. Authors wanted to compare them and point out the differences, aiming to both draw the attention to a need of unification and to provide a useful tool for clinicians. Endometrial cancer is the most common gynecological malignancy in Europe and its management involves a variety of health professionals. In recent years, big discoveries were made concerning the management of patients diagnosed with endometrial cancer, particularly in the field of molecular biology and minimally invasive surgery. This requires the continuous updating of guidelines and protocols over the years. In this paper, we aim to summarize and compare common points and disparities among protocols for management of patients diagnosed with endometrial cancer by leading international gynecological oncological societies. We therefore systematically report the parallel among the guidelines based on the various steps patients with endometrial cancer usually undergo. The comparison between American and European protocols revealed some relevant disparities, in particular regarding surgical staging, molecular biology application as a prognostic tool and follow up regimens. This could possibly cause differences in interpreting and applying protocols in clinical practice in small centers, leading to a lack of adherence to guidelines or even prompting a confusing mix of them. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer
- Author
-
Indini, Alice, primary, Nigro, Olga, additional, Lengyel, Csongor György, additional, Ghidini, Michele, additional, Petrillo, Angelica, additional, Lopez, Salvatore, additional, Raspagliesi, Francesco, additional, Trapani, Dario, additional, Khakoo, Shelize, additional, and Bogani, Giorgio, additional
- Published
- 2021
- Full Text
- View/download PDF
11. Detection of Ovarian Cancer through Exhaled Breath by Electronic Nose: A Prospective Study
- Author
-
Raspagliesi, Francesco, primary, Bogani, Giorgio, additional, Benedetti, Simona, additional, Grassi, Silvia, additional, Ferla, Stefano, additional, and Buratti, Susanna, additional
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.